Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Closed 04-10 16:00:00 EDT

450.33

+1.11

+0.25%

High452.93	Low435.76	Vol10.70M
Open449.38	D1 Closing449.22	Amplitude3.82%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O128.40M	T/O Rate--	Tradable Shares0.00
P/B2.473313	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":450.3311,"timestamp":1775851199999,"preClose":449.21902,"halted":0,"volume":10695672,"delay":0,"changeRate":0.002476,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":1.112061,"latestTime":"04-10 16:00:00 EDT","open":449.38382,"high":452.93048,"low":435.75772,"amount":128399375.425037,"amplitude":0.038228,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.473313,"peRate":-7.005837,"turnoverRate":0.014336,"increases":2,"decrements":3,"flats":0,"marketCap":9684442816,"floatMarketCap":8969924272},"requestUrl":"/m/hq/s/BK4556/tweets","defaultTab":"tweets","newsList":[{"id":"2626514344","title":"Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws","url":"https://stock-news.laohu8.com/highlight/detail?id=2626514344","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626514344?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:04","pubTimestamp":1775855044,"startTime":"0","endTime":"0","summary":"The latest update is out from Intellia Therapeutics ( ($NTLA) ). On April 7, 2026, Intellia Therapeutics, Inc.’s board of directors adopted amendme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-adopts-fourth-amended-and-restated-bylaws?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-adopts-fourth-amended-and-restated-bylaws?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","LU1861558580.USD","LU1861559042.SGD","BK4139","NTLA","BK4588","BK4556","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626854148","title":"Intellia bylaws set US federal courts as exclusive forum for Securities Act claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2626854148","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626854148?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:17","pubTimestamp":1775852265,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics amended its bylaws effective April 7, 2026.Changes add a process for shareholders to cure facial deficiencies in timely notices for nominations or proposals.Revisions require Intellia to notify shareholders of any facial deficiencies in those notices.Bylaws name US federal district courts as exclusive forum for claims under Securities Act of 1933 or Securities Exchange Act of 1934, unless Intellia consents to an alternative forum in writing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9q2gy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1861558580.USD","BK4535","LU1861559042.SGD","BK4588","BK4556","BK4139","NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626311254","title":"This Nuclear Stock Had Its Best Day Ever. Cathie Wood's ARK Took the Moment to Sell. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2626311254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626311254?lang=en_us&edition=fundamental","pubTime":"2026-04-11 01:55","pubTimestamp":1775843700,"startTime":"0","endTime":"0","summary":"After BWX Technologies had its best day on record, Cathie Wood's ARK Invest shed shares of the nuclear play across two of its flagship funds.The sale included 2,639 shares by the ARK Innovation exchange-traded fund, which is concentrated in so-called disruptive technology and dominated by names such as Crispr Therapeutics and Advanced Micro Devices. As of Friday, ARK Innovation held 303,133 BWX shares valued at roughly $69.8 million, or 1.17% of the portfolio by weight.The second fund to sell was the ARK Autonomous Technology & Robotics ETF, which shed 839 shares. BWX is the fund's 18th-largest holding by weight, comprising 2.08% of the portfolio. The fund holds 173,687 shares, which were valued at nearly $40 million on Friday.BWX has been a notably strong performer this year, surging 34% against a 0.4% decline for the S&P 500. The stock more than doubled in 2025, driven higher by backlog growth and contract wins with both government and commercial clients. The company counts the Defen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKK","BK4567","LU0240877869.USD","BK4606","ARKW","IE00B66KJ199.SGD","BK4187","BK4611","IE00B19Z4B17.USD","BK4585","SARK","IE0031619046.USD","SG9999014021.USD","ARKG","ARKX","LU0205194284.USD","LU1861558580.USD","CRSP","LU0240878834.USD","IE00B7SZL793.SGD","ARKF","SG9999014005.SGD","LU0205193047.USD","SG9999014013.SGD","BK4556","BK4544","BK4591","BK4139","ARKQ","LU1861559042.SGD","BK4588","BWXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626318228","title":"Is CRISPR Therapeutics (CRSP) Pricing Reflect Its Sharp Five‑Year Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2626318228","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626318228?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:27","pubTimestamp":1775734038,"startTime":"0","endTime":"0","summary":"Wondering whether CRISPR Therapeutics at around US$51.76 is offering fair value or a potential mispricing opportunity? This article breaks down the numbers for you in plain terms.\nThe stock has seen a 6.0% gain over the last week, an 11.9% decline over the past month, and a 3.7% decline year to date, while still showing a 48.4% return over the last year and 19.1% over three years, alongside a 58.0% decline over five years.\nRecent attention on CRISPR Therapeutics has focused on its position...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-pricing-reflect-its-sharp-fiveye","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-pricing-reflect-its-sharp-fiveye","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRSP","BK4588","BK4585","BK4139","BK4556","DCF","BK4611","LU1861558580.USD","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625966349","title":"Editas Medicine replaces Ernst & Young with PwC as auditor for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625966349","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625966349?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:29","pubTimestamp":1775593761,"startTime":"0","endTime":"0","summary":"Editas Medicine replaced Ernst & Young with PwC as independent auditor for fiscal year ending Dec. 31, 2026, effective April 1, 2026.Audit committee dismissed Ernst & Young following a formal review of proposals from other accounting firms.Ernst & Young audit reports for 2024 and 2025 carried no adverse opinion, disclaimer, or qualification.Editas reported no prior consultations with PwC on accounting, audit opinions, disagreements, or reportable events through April 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL54MNhx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625958035","title":"CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2625958035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625958035?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:00","pubTimestamp":1775563200,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, April  07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham V","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3269071/0/en/CRISPR-Therapeutics-to-Present-at-the-25th-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","BK4611","LU1861559042.SGD","BK4585","LU0128526141.USD","XBI","BK4139","HCSG","XLV","CRSP","LU1861558580.USD","BK4137","BK4588","BK4581","LABU","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625670069","title":"Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2625670069","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625670069?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:15","pubTimestamp":1775488504,"startTime":"0","endTime":"0","summary":"In early April 2026, Beam Therapeutics reported Phase 1/2 BEACON data for its investigational sickle cell therapy risto-cel in The New England Journal of Medicine, alongside encouraging BEAM-302 results in alpha-1 antitrypsin deficiency and continued regulatory engagement with the FDA.\nThe risto-cel data highlighted rapid engraftment, anemia resolution, and absence of severe vaso-occlusive crises post-treatment, reinforcing confidence in Beam’s base-editing platform and its potential to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/why-beam-therapeutics-beam-is-up-126-after-nejm-base-editing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/why-beam-therapeutics-beam-is-up-126-after-nejm-base-editing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","LU1861558580.USD","BK4556","BEAM","BK4139","BK4611","BK4505","BK4588","LU1861559042.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624851664","title":"Intellia grants 67,150 inducement RSUs to 13 new employees under 2024 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624851664","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624851664?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:05","pubTimestamp":1775246715,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics awarded inducement equity grants to 13 new employees on April 1, 2026.Grants totaled 67,150 time-based restricted stock units tied to Intellia common stock.RSUs vest one-third annually over three years, subject to continued service through each vesting date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL3MF3hp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4556","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","LU1861559042.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4535","NDAQ","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014039.USD","LU1861558580.USD","BK4112","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","NTLA","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664653","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664653","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664653?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:05","pubTimestamp":1775246700,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April  03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/03/3268135/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4535","BK4588","BK4139","NTLA","LU1861559042.SGD","BK4585","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624829726","title":"CRISPR Therapeutics announces annual shareholder meeting, releases preliminary proxy statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624829726","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624829726?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:24","pubTimestamp":1775161499,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics scheduled 2026 annual general meeting for June 4, 2026 in Zurich, Switzerland.Shareholders will vote on approval of 2025 Swiss management report, consolidated financial statements, statutory financial statements.Ballot includes proposal to carry forward 2025 net loss of CHF 508,714,076.Meeting will vote on board and committee elections, including re-election of Samarth Kulkarni as chairman.Other items include compensation limits, capital band increase, conditional share capital increase for convertible instruments, adoption of 2026 stock option and incentive plan, re-election of voting representative, re-election of auditors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the origina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8XSYLs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CRSP","BK4588","LU1861558580.USD","LU1861559042.SGD","BK4611","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624475415","title":"Beam Therapeutics CEO John M. Evans disposes of $1.1 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624475415","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624475415?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:32","pubTimestamp":1775082774,"startTime":"0","endTime":"0","summary":"Beam CEO John M. Evans reported sale of 50,000 shares on March 30-31.Evans ended March 31 with 1,076,667 shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL3wyV8V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Beam Therapeutics CEO John M. Evans disposes of $1.1 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BEAM","BK4611","BK4505","LU1861558580.USD","BK4556","BK4535","LU1861559042.SGD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624203544","title":"Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624203544","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624203544?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:20","pubTimestamp":1775078415,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) announced the publication of data from the ongoing Phase 1/2 BEACON clinical trial evaluating ristoglogene autogetemcel – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-risto-cel-shows-efficacy-in-sickle-cell-disease-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-risto-cel-shows-efficacy-in-sickle-cell-disease-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","LU1861559042.SGD","BK4539","LENZ","BK4588","BK4585","LU1861558580.USD","BK4535","BK4556","BEAM","BK4007","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624544152","title":"Beam risto-cel BEACON trial data in NEJM support BLA filing by late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624544152","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624544152?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:12","pubTimestamp":1775077957,"startTime":"0","endTime":"0","summary":"Beam Therapeutics reported interim Phase 1/2 BEACON trial results for investigational sickle cell therapy risto-cel in New England Journal of Medicine.Data were initially presented at American Society of Hematology annual meeting, then updated in journal publication.Study showed patients had sustained improvement in disease biology with elimination of severe pain crises following engraftment.Beam expects U.S. BLA submission for risto-cel as early as year-end 2026.Company pegged eligible U.S. sickle cell population for gene therapies at about 10,000 patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2TZCpv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BEAM","BK4588","BK4556","BK4535","IE00B3QW5Z07.USD","BK4112","BK4585","SG9999014039.USD","LU0314104364.USD","SG9999014021.USD","LU1861558580.USD","BK4139","BK4505","NDAQ","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD","BK4611","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623535337","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623535337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623535337?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:40","pubTimestamp":1774971609,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Gal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-terns-pharmaceuticals-tern-sangamo-therapeutics-sgmo-and-galectin-therapeutics-galt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-terns-pharmaceuticals-tern-sangamo-therapeutics-sgmo-and-galectin-therapeutics-galt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TERN","LU0128526141.USD","LU0320765992.SGD","SGMO","BK4588","BK4581","XLV","BK4139","BK4137","LABU","BK4556","GALT","LU0109394709.USD","BK4007","BK4585","LU0889565916.HKD","XBI","HCSG","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623274823","title":"Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2623274823","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623274823?lang=en_us&edition=fundamental","pubTime":"2026-03-31 07:15","pubTimestamp":1774912513,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummarySangamo Therapeutics Inc SGMO.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL8N40I26B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","SGMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623299963","title":"Sangamo reports Q4 EPS (11c), consensus (5c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623299963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623299963?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:14","pubTimestamp":1774901668,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $14.23M vs. $7.55M last year. “Sangamo (SGMO) continued to make significant pipeline progress since the start of 2025. Following...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sangamo-reports-q4-eps-11c-consensus-5c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sangamo-reports-q4-eps-11c-consensus-5c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMO","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329393","title":"Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329393?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:13","pubTimestamp":1774901594,"startTime":"0","endTime":"0","summary":"Sangamo repositioned strategy around neurology-focused genomic medicines built on zinc-finger epigenetic regulation cargo, supported by STAC-BBB CNS delivery platform.Chronic neuropathic pain candidate ST-503 entered Phase 1/2 STAND study in small fiber neuropathy; U.S. FDA granted Fast Track designation.Prion disease program ST-506 advanced CTA-enabling work; GLP toxicology study completed with analysis ongoing.Fabry gene therapy ST-920 moved through rolling BLA submission under Accelerated Approval; completion targeted as early as summer 2026 subject to additional funding.Liquidity outlook indicated operations funded into Q3 2026; cash and cash equivalents totaled USD 21 million as of Dec. 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4B6zMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329385","title":"Sangamo Q4 revenue misses analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329385","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329385?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:11","pubTimestamp":1774901466,"startTime":"0","endTime":"0","summary":"Sangamo Q4 revenue misses analyst expectationsOverviewGenomic medicine firm's Q4 revenue rose yr/yr but missed analyst expectationsCompany posted Q4 net loss of $37.4 mln, or $0.11 per shareRaised ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL1N40I0YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0289739699.SGD","SG9999003800.SGD","LU0306807586.USD","LU0321505868.SGD","BK4550","BK4007","BK4599","LU0122379950.USD","LU0058720904.USD","LU0868494617.USD","LU1057294990.SGD","LU1066051498.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","BK4588","IE00BLSP4239.USD","LU0170899867.USD","LU0321505439.SGD","LU0234572021.USD","BK4592","LU0225771236.USD","SG9999001176.SGD","IE0002270589.USD","SG9999002224.SGD","SG9999002232.USD","SG9999013999.USD","LU0456855351.SGD","BK4581","BK4534","BK4139","LU1066053197.SGD","SGXZ57979304.SGD","LU0225284248.USD","IE00BLSP4452.SGD","IE00B19Z3581.USD","LU1883839398.USD","SGMO","LU1023059063.AUD","LU1894683348.USD","LU0985481810.HKD","LU0306806265.USD","SG9999001176.USD","BK4556","BK4568","BK4533","LU1894683264.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623267493","title":"Sangamo FY25 net loss widens to $123 million; revenue drops to $40 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623267493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623267493?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901119,"startTime":"0","endTime":"0","summary":"Sangamo posted a net loss of $37 million in Q4, or $0.11 per share.Total operating expenses rose to $52 million, driven by impairment charges and higher clinical and manufacturing costs tied to Fabry BLA readiness.Rolling BLA submission for Fabry gene therapy ST-920 is underway, with completion targeted as early as summer 2026 subject to funding.Outlook: 2026 GAAP operating expenses seen at about $120 million-$140 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL1kn3Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","SGMO","BK4556","BK4588","SG9999014021.USD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623232623","title":"BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2623232623","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623232623?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:01","pubTimestamp":1774900905,"startTime":"0","endTime":"0","summary":"BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11\n\n\nMar 30 (Reuters) - Sangamo Therapeutics Q4 operating income USD -38.203 million.\n\nQ4 revenue USD 14.228 million\nQ4 net income USD -37.419 million\nQ4 operating expenses USD 52.4 million\nQ4 adjusted operating expenses USD 36 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLX9BCEC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}